Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
1.45
USD
|
+2.84%
|
|
-7.94%
|
-21.20%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
535.1
|
143
|
175.9
|
166.5
|
166.3
|
-
|
-
|
Enterprise Value (EV)
1 |
500.7
|
120.3
|
157.9
|
166.5
|
166.3
|
166.3
|
166.3
|
P/E ratio
|
-3.11
x
|
-3.35
x
|
-1.48
x
|
-2.88
x
|
-3.88
x
|
-5.44
x
|
-10.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
11.7
x
|
2.62
x
|
4.6
x
|
3.39
x
|
2.49
x
|
2.01
x
|
1.66
x
|
EV / Revenue
|
11.7
x
|
2.62
x
|
4.6
x
|
3.39
x
|
2.49
x
|
2.01
x
|
1.66
x
|
EV / EBITDA
|
-26,712,242
x
|
-3,786,195
x
|
-3,744,196
x
|
-4,379,344
x
|
-
|
-
|
-
|
EV / FCF
|
-
|
-4.69
x
|
-3.64
x
|
-
|
-3.23
x
|
-12
x
|
-47.5
x
|
FCF Yield
|
-
|
-21.3%
|
-27.4%
|
-
|
-31%
|
-8.36%
|
-2.1%
|
Price to Book
|
13
x
|
8.26
x
|
8.66
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
26,541
|
27,027
|
76,496
|
90,476
|
114,686
|
-
|
-
|
Reference price
2 |
20.16
|
5.290
|
2.300
|
1.840
|
1.450
|
1.450
|
1.450
|
Announcement Date
|
3/16/21
|
3/14/22
|
3/6/23
|
3/1/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
24.55
|
45.56
|
54.51
|
38.21
|
49.09
|
66.77
|
82.57
|
100.1
|
EBITDA
|
-
|
-20.03
|
-37.76
|
-46.99
|
-38.01
|
-
|
-
|
-
|
EBIT
1 |
-
|
-22.93
|
-40.94
|
-50.59
|
-41.34
|
-35.2
|
-28.65
|
-10.5
|
Operating Margin
|
-
|
-50.34%
|
-75.11%
|
-132.39%
|
-84.22%
|
-52.72%
|
-34.7%
|
-10.49%
|
Earnings before Tax (EBT)
1 |
-
|
-31.35
|
-43.16
|
-65.45
|
-52.15
|
-45.45
|
-38.9
|
-20.6
|
Net income
1 |
-30.73
|
-31.35
|
-43.16
|
-65.45
|
-52.15
|
-45.45
|
-38.9
|
-20.6
|
Net margin
|
-125.15%
|
-68.81%
|
-79.18%
|
-171.27%
|
-106.23%
|
-68.07%
|
-47.11%
|
-20.58%
|
EPS
2 |
-21.31
|
-6.480
|
-1.580
|
-1.550
|
-0.6400
|
-0.3733
|
-0.2667
|
-0.1400
|
Free Cash Flow
1 |
-
|
-
|
-30.46
|
-48.27
|
-
|
-51.5
|
-13.9
|
-3.5
|
FCF margin
|
-
|
-
|
-55.89%
|
-126.32%
|
-
|
-77.13%
|
-16.83%
|
-3.5%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/2/20
|
3/16/21
|
3/14/22
|
3/6/23
|
3/1/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
7.224
|
6.548
|
10.95
|
11.11
|
9.608
|
9.056
|
11.87
|
13.49
|
14.67
|
14.82
|
16.17
|
17.23
|
18.53
|
18.8
|
20
|
EBITDA
|
-10.82
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-11.68
|
-14.38
|
-11.63
|
-10.61
|
-13.89
|
-16.37
|
-10.93
|
-7.172
|
-6.87
|
-11.02
|
-8.75
|
-7.85
|
-7.55
|
-9.6
|
-6.1
|
Operating Margin
|
-161.67%
|
-219.61%
|
-106.17%
|
-95.53%
|
-144.56%
|
-180.8%
|
-92.04%
|
-53.16%
|
-46.84%
|
-74.38%
|
-54.12%
|
-45.55%
|
-40.74%
|
-51.06%
|
-30.5%
|
Earnings before Tax (EBT)
1 |
-13.28
|
-15.59
|
-15.82
|
-13.7
|
-20.34
|
-18.7
|
-13.36
|
-10.95
|
-9.139
|
-13.61
|
-11.35
|
-10.45
|
-10.1
|
-12.2
|
-8.6
|
Net income
1 |
-13.28
|
-15.59
|
-15.82
|
-13.7
|
-20.34
|
-18.7
|
-13.36
|
-10.95
|
-9.139
|
-13.61
|
-11.35
|
-10.45
|
-10.1
|
-12.2
|
-8.6
|
Net margin
|
-183.86%
|
-238.03%
|
-144.51%
|
-123.34%
|
-211.67%
|
-206.52%
|
-112.5%
|
-81.16%
|
-62.31%
|
-91.87%
|
-70.21%
|
-60.64%
|
-54.5%
|
-64.89%
|
-43%
|
EPS
2 |
-0.4900
|
-0.5000
|
-0.4000
|
-0.3400
|
-0.3500
|
-0.2400
|
-0.1700
|
-0.1400
|
-0.1000
|
-0.1400
|
-0.0933
|
-0.0767
|
-0.0733
|
-0.1000
|
-0.0600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/14/22
|
5/11/22
|
8/4/22
|
11/3/22
|
3/6/23
|
5/11/23
|
8/7/23
|
11/7/23
|
3/1/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
34.4
|
22.7
|
18
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-30.5
|
-48.3
|
-
|
-51.5
|
-13.9
|
-3.5
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-142%
|
-325%
|
-414%
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
1.550
|
0.6400
|
0.2700
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1.95
|
2.24
|
3.3
|
-
|
7
|
7.7
|
8.5
|
Capex / Sales
|
-
|
4.27%
|
4.11%
|
8.63%
|
-
|
10.48%
|
9.33%
|
8.49%
|
Announcement Date
|
10/2/20
|
3/16/21
|
3/14/22
|
3/6/23
|
3/1/24
|
-
|
-
|
-
|
Last Close Price
1.45
USD Average target price
3.25
USD Spread / Average Target +124.14% Consensus |
1st Jan change
|
Capi.
|
---|
| -21.20% | 166M | | -23.07% | 7.86B | | +68.36% | 4.32B | | +1.88% | 2.63B | | -8.06% | 2.5B | | -41.95% | 2.33B | | -11.99% | 1.82B | | -21.18% | 1.51B | | +17.44% | 1.22B | | -43.89% | 1.14B |
Medical & Diagnostic Laboratories
|